Clinical Trial Update: A Phase 1 Study to Investigate the Safety and Pharmacokinetics of Fosigotifator in Patients With Amyotrophic Lateral Sclerosis [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating the safety and pharmacokinetics of Fosigotifator in patients with Amyotrophic Lateral Sclerosis has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Drugs mentioned

• Fosigotifator (ABBV-CLS-7262)

Snippet

Sponsor: AbbVie | Conditions: ALS, Amyotrophic Lateral Sclerosis | Phase 1 | Status: TERMINATED